Bioage Labs, Stock Current Liabilities
| BIOA Stock | 19.70 0.63 3.30% |
BioAge Labs, fundamentals help investors to digest information that contributes to BioAge Labs,'s financial success or failures. It also enables traders to predict the movement of BioAge Stock. The fundamental analysis module provides a way to measure BioAge Labs,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioAge Labs, stock.
The current year's Non Current Liabilities Total is expected to grow to about 148.2 M, whereas Total Current Liabilities is forecasted to decline to about 30 M. BioAge | Current Liabilities |
BioAge Labs, Company Current Liabilities Analysis
BioAge Labs,'s Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current BioAge Labs, Current Liabilities | 29.68 M |
Most of BioAge Labs,'s fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioAge Labs, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioAge Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAge Labs, is extremely important. It helps to project a fair market value of BioAge Stock properly, considering its historical fundamentals such as Current Liabilities. Since BioAge Labs,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAge Labs,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAge Labs,'s interrelated accounts and indicators.
Click cells to compare fundamentals
BioAge Current Liabilities Historical Pattern
Today, most investors in BioAge Labs, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioAge Labs,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioAge Labs, current liabilities as a starting point in their analysis.
BioAge Labs, Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, BioAge Labs, has a Current Liabilities of 29.68 M. This is 99.52% lower than that of the sector and 89.74% lower than that of the Current Liabilities industry. The current liabilities for all United States stocks is 99.62% higher than that of the company.
BioAge Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAge Labs,'s direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioAge Labs, could also be used in its relative valuation, which is a method of valuing BioAge Labs, by comparing valuation metrics of similar companies.BioAge Labs, is currently under evaluation in current liabilities category among its peers.
BioAge Labs, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioAge Labs,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioAge Labs,'s managers, analysts, and investors.Environmental | Governance | Social |
BioAge Fundamentals
| Current Valuation | 539.05 M | ||||
| Shares Outstanding | 34.17 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 32.64 % | ||||
| Number Of Shares Shorted | 2.21 M | ||||
| Price To Earning | (0.84) X | ||||
| EBITDA | (45.81 M) | ||||
| Net Income | (63.85 M) | ||||
| Cash And Equivalents | 4.63 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 53.25 M | ||||
| Debt To Equity | 172.10 % | ||||
| Current Ratio | 1.35 X | ||||
| Book Value Per Share | (114.37) X | ||||
| Cash Flow From Operations | (37.36 M) | ||||
| Earnings Per Share | (5.40) X | ||||
| Number Of Employees | 56 | ||||
| Beta | 4.19 | ||||
| Market Capitalization | 674.12 M | ||||
| Total Asset | 25.92 M | ||||
| Retained Earnings | (181.7 M) | ||||
| Working Capital | (32.86 M) | ||||
| Current Asset | 10.84 M | ||||
| Current Liabilities | 29.68 M | ||||
| Net Asset | 25.92 M |
About BioAge Labs, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioAge Labs,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAge Labs, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioAge Labs, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioAge Labs, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs, Stock:Check out BioAge Labs, Piotroski F Score and BioAge Labs, Altman Z Score analysis. For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs,. If investors know BioAge will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAge Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.40) |
The market value of BioAge Labs, is measured differently than its book value, which is the value of BioAge that is recorded on the company's balance sheet. Investors also form their own opinion of BioAge Labs,'s value that differs from its market value or its book value, called intrinsic value, which is BioAge Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAge Labs,'s market value can be influenced by many factors that don't directly affect BioAge Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAge Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAge Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAge Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.